IntelGenx Technologies Corp (IGXT)

[Camaro1093]

IntelGenx to Present at BioFinance 2010

SAINT LAURENT, QUEBEC, Apr 07, 2010 (MARKETWIRE via COMTEX) -- IntelGenx Corp.
(CA:IGX)(IGXT) ("IntelGenx") today announced that that Dr. Horst Zerbe, President
and Chief Executive Officer, will present an overview of the Company at the
BioFinance 2010 Conference, which is taking place this week in Toronto. Dr. Zerbe
will be speaking this afternoon at 4:30pm EDT.

Dr. Zerbe will discuss advances made in our pipeline and technologies. In the
past year we filed an NDA for our high dose Bupropion XL product, and we received
excellent data on both our Relivar product (a novel buccal formulation of a
dronabinol) and on our thin film migraine product. These milestones validate our
best in class VersaTab, VersaFilm and AdVersa technologies.

About BioFinance 2010:

BioFinance 2010 is the leading investor conference in Canada for the life
sciences industry. This event brings together key industry players interested in
investment opportunities and issues affecting companies in the life sciences
sector.

About IntelGenx Corp.:

IntelGenx Corp. is a drug delivery company focused on the development of oral
controlled-release products as well as novel rapidly disintegrating delivery
systems. IntelGenx uses its unique multiple layer delivery system to provide
zero-order release of active drugs in the gastrointestinal tract. IntelGenx has
also developed novel delivery technologies for the rapid delivery of
pharmaceutically active substances in the oral cavity based on its experience
with rapidly disintegrating films. IntelGenx's research and development pipeline
includes products for the treatment of pain, hypertension, osteoarthritis and
depressive disorders. More information is available about the company at
http://www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx's operating
results and business prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934, as amended,
and Section 27A of the Securities Act of 1933, as amended. These statements
include, but are not limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of future events
or circumstances and are generally identified by the words "may," "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," "could,"
"would," and similar expressions. All forward looking statements are expressly
qualified in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and uncertainties,
IntelGenx's actual results could differ materially from those expressed or
implied by these forward looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, those discussed
under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K for
the fiscal year ended December 31, 2008, filed with the United States Securities
and Exchange Commission and available at http://www.sec.gov, and also filed with
Canadian securities regulatory authorities and http://www.sedar.com. IntelGenx
assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTC Bulletin Board has neither approved nor
disapproved the contents of this press release.

Contacts:
IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
[phone] (ext. 201)
[phone] (FAX)
[e-mail]
http://www.intelgenx.com




SOURCE: IntelGenx Corp.
mailto:[e-mail]
http://www.intelgenx.com


Copyright 2010 Marketwire, Inc., All rights reserved.